Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vipshop Holdings Ltd - ADR — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.17 (market cap $29.60B), while Vipshop Holdings Ltd - ADR trades at $14.46 (market cap $7.20B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.1× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays a 4.14% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VIPS | |
|---|---|---|
Market Cap | $29.60B | $7.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $20.68 |
52-Week Low | $205.48 | $12.92 |
Enterprise Value | $27.56B | $3.76B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
VIPS stock trades at $14.31, down 7.14% over 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 EPS of $0.68, meeting expectations, and maintains strong profitability with a net income margin of 7.07%. Recent news highlights growth initiatives, including an outlet strategy to boost performance amid industry challenges.
The outlook for VIPS is cautiously optimistic, supported by low valuation multiples like a P/E of 6.79 and a buy consensus from 53.57% of analysts. Risks include revenue stagnation and macroeconomic pressures, but the stock's discounted valuation may offer upside if growth resumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
